Information Provided By:
Fly News Breaks for September 23, 2015
HZNP
Sep 23, 2015 | 07:40 EDT
Stifel believes that Horizon Pharma's stock has been pressured in recent days due to worries about prescription trends and statements about drug pricing. However, the firm thinks that the company is on track to beat Q3 revenue expectations and its 2015 revenue guidance. It does not expect the "rhetoric" about drug pricing to impact the company and it keeps a $45 price target and Buy rating on the shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP